BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Olema Pharmaceuticals\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Olema Pharmaceuticals\, Inc.'s dr
 ugs run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07085767-2666@assetmemo.bio
DTSTAMP:20261121T005928Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Palazestrant: Phase 3 readout est. (NCT07085767)
DESCRIPTION:Palazestrant\, phase 3\, HR+/HER2- Metastatic Breast Cancer.\nS
 tudy: Palazestrant in Combination With Ribociclib for the First-line Treat
 ment of ER+/HER2- Advanced Breast Cancer\nEstimated primary completion: De
 cember 2028. This is a ClinicalTrials.gov estimate\, not a confirmed reado
 ut date\, and it can move.\nDrug page: https://assetmemo.bio/drug/palazest
 rant#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07085767
URL:https://assetmemo.bio/drug/palazestrant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
